AZ's selumetinib fails in Phase III NSCLC study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said selumetinib ( ARRY-886, AZD6244) plus docetaxel missed the primary endpoint in the Phase III SELECT-1 study to treat K-Ras (KRAS) mutation-positive non-small cell lung cancer. The combo failed to significantly improve progression-free survival (PFS) vs. placebo as a second-line therapy in the 510-patient study.

Array BioPharma Inc. (NASDAQ:ARRY) sank $1.01 (23%) to $3.44 on the news. The biotech granted AstraZeneca rights to selumetinib in 2003. ...